BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Presgraves SP, Borwege S, Millan MJ, Joyce JN. Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Experimental Neurology 2004;190:157-70. [DOI: 10.1016/j.expneurol.2004.06.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Chao CC, Shen PW, Tzeng TY, Kung HJ, Tsai TF, Wong YH. Human iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging. Biomedicines 2021;9:1635. [PMID: 34829864 DOI: 10.3390/biomedicines9111635] [Reference Citation Analysis]
2 Gonçalves ECD, Lieberknecht V, Horewicz VV, Rabelo BD, Felipetti FA, Rodrigues ALS, Martins DF, Dutra RC. Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis. Mol Neurobiol 2021;58:5971-85. [PMID: 34432265 DOI: 10.1007/s12035-021-02507-6] [Reference Citation Analysis]
3 Pankiewicz P, Szybiński M, Kisielewska K, Gołębiowski F, Krzemiński P, Rutkowska-Włodarczyk I, Moszczyński-Pętkowski R, Gurba-Bryśkiewicz L, Delis M, Mulewski K, Smuga D, Dominowski J, Janusz A, Górka M, Abramski K, Napiórkowska A, Nowotny M, Dubiel K, Kalita K, Wieczorek M, Pieczykolan J, Matłoka M. Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists. Pharmaceuticals (Basel) 2021;14:704. [PMID: 34451801 DOI: 10.3390/ph14080704] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 El Manaa W, Duplan E, Goiran T, Lauritzen I, Vaillant Beuchot L, Lacas-Gervais S, Morais VA, You H, Qi L, Salazar M, Ozcan U, Chami M, Checler F, Alves da Costa C. Transcription- and phosphorylation-dependent control of a functional interplay between XBP1s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology. Autophagy 2021;:1-23. [PMID: 34030589 DOI: 10.1080/15548627.2021.1917129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang P, Knight WC, Li H, Guo Y, Perlmutter JS, Benzinger TLS, Morris JC, Xu J. Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features. Ann Clin Transl Neurol 2021;8:224-37. [PMID: 33348472 DOI: 10.1002/acn3.51274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J. Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment? Ageing Res Rev 2020;57:100994. [PMID: 31765822 DOI: 10.1016/j.arr.2019.100994] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 18.5] [Reference Citation Analysis]
7 Ko KR, Tam NW, Teixeira AG, Frampton JP. SH-SY5Y and LUHMES cells display differential sensitivity to MPP+, tunicamycin, and epoxomicin in 2D and 3D cell culture. Biotechnol Prog 2020;36:e2942. [PMID: 31756288 DOI: 10.1002/btpr.2942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Huang C, Ma J, Li BX, Sun Y. Wnt1 silencing enhances neurotoxicity induced by paraquat and maneb in SH-SY5Y cells. Exp Ther Med 2019;18:3643-9. [PMID: 31602242 DOI: 10.3892/etm.2019.7963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Motyl J, Przykaza Ł, Boguszewski PM, Kosson P, Strosznajder JB. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology 2018;135:139-50. [DOI: 10.1016/j.neuropharm.2018.02.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
10 Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener 2017;12:10. [PMID: 28118852 DOI: 10.1186/s13024-017-0149-0] [Cited by in Crossref: 306] [Cited by in F6Publishing: 271] [Article Influence: 61.2] [Reference Citation Analysis]
11 Zhang Y, Liu F, Zhang X, Xu T, Quan W, Wang H, Shi J, Dai Z, Wu B, Wu Q. Recognition and identification of active components from Radix Bupleuri using human neuroblastoma SH-SY5Y cells: Recognition and identification of active components by SH-SY5Y cells. Biomed Chromatogr 2016;30:440-6. [DOI: 10.1002/bmc.3567] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
12 Chiu W, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel W, Ries V, Höglinger G. Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Neuropharmacology 2015;95:367-76. [DOI: 10.1016/j.neuropharm.2015.03.020] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
13 Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics 2014;6:81-9. [DOI: 10.1586/14737175.6.1.81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
14 Knaryan VH, Samantaray S, Park S, Azuma M, Inoue J, Banik NL. SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone. J Neurochem 2014;130:280-90. [PMID: 24341912 DOI: 10.1111/jnc.12629] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
15 Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson's disease. Expert Opin Investig Drugs 2014;23:387-410. [PMID: 24313341 DOI: 10.1517/13543784.2014.869209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
16 Pandya CD, Hoda MN, Kutiyanawalla A, Buckley PF, Pillai A. Differential effects upon brain and serum BDNF levels in rats as response to continuous and intermittent administration strategies of two second generation antipsychotics. Schizophrenia Research 2013;151:287-8. [DOI: 10.1016/j.schres.2013.09.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Harkavyi A, Rampersaud N, Whitton PS. Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra. J Neurodegener Dis 2013;2013:407152. [PMID: 26316987 DOI: 10.1155/2013/407152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chau KY, Cooper JM, Schapira AH. Pramipexole reduces phosphorylation of α-synuclein at serine-129. J Mol Neurosci 2013;51:573-80. [PMID: 23681749 DOI: 10.1007/s12031-013-0030-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
19 Park G, Park Y, Yang HO, Oh MS. Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. Pharmacology Biochemistry and Behavior 2013;104:163-8. [DOI: 10.1016/j.pbb.2013.01.017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
20 Tasaki Y, Yamamoto J, Omura T, Noda T, Kamiyama N, Yoshida K, Satomi M, Sakaguchi T, Asari M, Ohkubo T, Shimizu K, Matsubara K. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity. European Journal of Pharmacology 2012;676:57-63. [DOI: 10.1016/j.ejphar.2011.11.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
21 Constantinescu R. Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008;4:337-52. [PMID: 18728740 DOI: 10.2147/ndt.s2325] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
22 Greene LA, Levy O, Malagelada C. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol 2011;31:969-78. [PMID: 21547489 DOI: 10.1007/s10571-011-9671-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
23 Merlo S, Canonico PL, Sortino MA. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype. Neuropharmacology 2011;60:892-900. [PMID: 21272591 DOI: 10.1016/j.neuropharm.2011.01.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
24 Li C, Biswas S, Li X, Dutta AK, Le W. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. J Neurosci Res 2010;88:2513-23. [PMID: 20623619 DOI: 10.1002/jnr.22405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 26] [Article Influence: 0.6] [Reference Citation Analysis]
25 Millan MJ. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther 2010;128:229-73. [PMID: 20600305 DOI: 10.1016/j.pharmthera.2010.06.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
26 Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 2010;120:1774-85. [PMID: 20407211 DOI: 10.1172/JCI41356] [Cited by in Crossref: 261] [Cited by in F6Publishing: 132] [Article Influence: 21.8] [Reference Citation Analysis]
27 Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 2008;86:186-215. [PMID: 18824211 DOI: 10.1016/j.pneurobio.2008.09.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
28 Imamura K, Takeshima T, Nakaso K, Ito S, Nakashima K. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neuroscience Letters 2008;440:97-102. [DOI: 10.1016/j.neulet.2008.05.067] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
29 Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008;15 Suppl 1:5-13. [PMID: 18353131 DOI: 10.1111/j.1468-1331.2008.02055.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
30 Tanaka K, Okada Y, Kanno T, Otomo A, Yanagisawa Y, Shouguchi-miyata J, Suga E, Kohiki E, Onoe K, Osuga H, Aoki M, Hadano S, Itoyama Y, Ikeda J. A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Experimental Neurology 2008;211:378-86. [DOI: 10.1016/j.expneurol.2008.02.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
31 Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Schapira AH, Jenner P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 2008;212:522-31. [PMID: 18571649 DOI: 10.1016/j.expneurol.2008.04.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
32 Biswas S, Hazeldine S, Ghosh B, Parrington I, Kuzhikandathil E, Reith MEA, Dutta AK. Bioisosteric Heterocyclic Versions of 7-{[2-(4-Phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: Identification of Highly Potent and Selective Agonists for Dopamine D3 Receptor with Potent in Vivo Activity. J Med Chem 2008;51:3005-19. [DOI: 10.1021/jm701524h] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
33 Nair VD, Olanow CW. Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem 2008;283:15469-78. [PMID: 18387957 DOI: 10.1074/jbc.M707238200] [Cited by in Crossref: 63] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
34 Riveles K, Huang LZ, Quik M. Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. Neurotoxicology 2008;29:421-7. [PMID: 18359086 DOI: 10.1016/j.neuro.2008.02.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
35 Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Mov Disord 2006;21:2090-5. [PMID: 16991143 DOI: 10.1002/mds.21106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
36 Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behavioural Pharmacology 2006;17:559-72. [DOI: 10.1097/01.fbp.0000236267.41806.5b] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
37 Chiasson K, Daoust B, Levesque D, Martinoli MG. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. Neurotox Res 2006;10:31-42. [PMID: 17000468 DOI: 10.1007/BF03033332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Chen S, Le W. Neuroprotective therapy in Parkinson disease. Am J Ther 2006;13:445-57. [PMID: 16988541 DOI: 10.1097/01.mjt.0000174353.28012.a7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
39 Millan MJ, Iob L, Péglion JL, Dekeyne A. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology (Berl) 2007;191:767-82. [PMID: 17047933 DOI: 10.1007/s00213-006-0567-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
40 Boeckler F, Gmeiner P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol Ther 2006;112:281-333. [PMID: 16905195 DOI: 10.1016/j.pharmthera.2006.04.007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
41 Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 2006;110:135-370. [DOI: 10.1016/j.pharmthera.2005.11.006] [Cited by in Crossref: 385] [Cited by in F6Publishing: 355] [Article Influence: 24.1] [Reference Citation Analysis]
42 Fumagalli F, Racagni G, Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 2006;6:95-104. [DOI: 10.1038/sj.tpj.6500360] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
43 Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. European Journal of Neuroscience 2005;22:2422-30. [DOI: 10.1111/j.1460-9568.2005.04438.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
44 Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K, Schild L, Hengerer B, Ludolph AC, Dorner-ciossek C, Kussmaul L. Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole Dihydrochloride]. J Pharmacol Exp Ther 2005;316:189-99. [DOI: 10.1124/jpet.105.092312] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]